Chemokines in homeostasis and cancers

Yakhteh

Volumn 10, Issue 3, 2008, Pages 155-166

  Abroun, Saeid ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Chemokine receptors; Chemokines; CXCR4; SDF 1

Indexed keywords

BEVACIZUMAB; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CX3C CHEMOKINE; CXCL13 CHEMOKINE; CXCL14 CHEMOKINE; CXCL16 CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CXCL12; PLERIXAFOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; BONE MARROW METASTASIS; CANCER IMMUNOLOGY; CARCINOGENESIS; CELL ADHESION; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG TARGETING; GLIOBLASTOMA; HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LYMPH NODE METASTASIS; METASTASIS; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PATHOGENESIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; THYROID CANCER; TUMOR VASCULARIZATION;

EID: 52149088567     PISSN: 15614921     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Bacon K, Baggiolini M, Broxmeyer H, et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002;22:1067-1068
2. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000; 12: 121-127
3. Rossi D, Zlotnik A. The biology of chemokines and their recveptor. Annu Rev Immunol, 2000; 8: 217-242
4. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004; 25: 75-84
5. Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 2005; 42: 799-8096
6. Ishida T, Ida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res 2004; 10: 7529-7539
7. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry co-factor, functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877
8. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997; 385: 645-649
9. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000; 52: 145-176
10. Thelen M. Dancing to the tune of chemokines. Nat Immunol, 2001; 2: 129-134
11. Broxmeyer HE, Kim CH. Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Exp Hematol. 1999; 27: 1113-1123
12. Broxmeyer HE, Kim CH, Cooper SH, Hangoc G, Hromas R, Pelus LM. Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Ann NY Acad Sci. 1999; 872: 142-162
13. Cooper S, Mantel C, Broxmeyer HE. Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha. Exp Hematol. 1994; 22: 186-193
14. Broxmeyer HE, Cooper S, Hangoc G, Gao JL, Murphy PM. Dominant myelopoietic effector functions mediated bychemokine receptor CCR1. J Exp Med. 1999; 189: 1987-1992
15. D'Apuzzo M, Rolink A, Loetscher M, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol. 1997; 27: 1788-1793
16. Aiuti A, Tavian M, Cipponi A, et al. Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. Eur J Immunol. 1999; 29: 1823-1831
17. Tachibana K, Hirota s, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998; 393: 591-594
18. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998; 393: 595-599
19. Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA. 1998; 95: 9448-9453
20. Bleul CC, Boehm T. Chemokines define distinct microenvironments in the developing thymus. Eur J Immunol. 2000; 30: 3371-3379
21. Vicari AP, Figueroa DJ, Hedrick JA, et al. TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity. 1997; 7: 291-301
22. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell. 1996; 87: 1037-1047
23. Ansel KM, Ngo VN, Hyman PL, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000; 406: 309-314
24. Luster AD. Chemokines chemotactic cytokines that mediate inflammation. N Engl J Med. 1998; 338: 436-445
25. Yingying Le, Ye Zhou1, Pablo Iribarren and Ji Ming Wang. Chemokines and Chemokine Receptors: Their Manifold Roles in Homeostasis and Disease. Cellular and Molecular Immunology. 2004; 2: 95-104
26. Baekkevold ES, Yamanaka T, Palframan RT, et al. The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J Exp Med. 2001; 193: 1105-1112
27. Reif K, Ekland EH, Ohl L, et al. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature. 2002;416:94-99
28. Muller G, Hopken UE, Lipp M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev. 2003; 195: 117-135
29. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ. Interferon γ-inducible protein 10 (IP-10), member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun. 1995; 210: 51-57
30. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995; 270: 27348-27357
31. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1-alpha. Am J Pathol. 1999; 154: 1125-1135
32. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst. 1998; 90: 447-454
33. Arenberg DA, Polverini PJ, Kunkel SL, et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol. 1997; 62: 554-562
34. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 1996; 97: 2792-2802
35. Standiford TJ, Kunkel SL, Lukacs NW, et al. Macrophage inflammatory protein-1 alpha mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. J Immunol. 1995; 155: 1515-1524
36. VanOtteren GM, Strieter RM, Kunkel SL, et al. Compartmentalized expression of RANTES in a murine model of endotoxemia. J Immunol. 1995; 154: 1900-1908
37. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol. 1995; 155: 2222-2229
38. Van Zee KJ, DeForge LE, Fischer E, et al. IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol. 1991; 146: 3478-3482
39. D'Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F. Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Grit Care Med. 2001; 164: 1266-1275
40. Burke-Gaffney A, Brooks AV, Bogle RG. Regulation of chemokine expression in atherosclerosis. Vascul Pharmacol. 2002; 38: 283-292
41. Quyyumi AA, Murphy PM. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. yingying 2001; 89: 401-407
42. Szekanecz Z, Koch AE. Chemokines and angiogenesis. Curr Opin Rheumatol. 2001; 13: 202-208
43. Nanki T, Hayashida K, El-Gabalawy HS, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+T cell accumulation in rheumatoid arthritis synovium. J Immunol. 2000; 165: 6590-6598
44. Nanki T, Hayashida K, El-Gabalawy HS, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+T cell accumulation in rheumatoid arthritis synovium. J Immunol. 2000; 165: 6590-6598
45. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science. 1983; 219: 308-310
46. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol. 998; 86: 20-29
47. Sorensen TL, Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology. 2001; 57: 1371-1376
48. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A. 1999; 96: 6873-6878.
49. Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN. Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol. 2000; 108: 192-200
50. Karpus WJ, Kennedy KJ. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol. 1997; 62: 681-687
51. Liu MT, Keirstead HS, Lane TE. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. J Immunol. 2001; 167: 4091-4097
52. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med. 2000; 192: 1075-1080
53. Rottman JB, Slavin AJ, Silva R, Weiner HL, Gerard CG, Hancock WW. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol. 2000; 30: 2372-2377
54. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004; 14(3): 171-179
55. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res, 2000; 6: 3530-3535
56. Rempl SA, Dudas S, Ge S, Gutierrez JA, Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res, 2000; 6: 102-111
57. Geminder H, Sagi-Agl-Assif O, Goldberg L, et al. A Possible Role for CXCR4 and Its Ligand, the CXC Chemokine Stromal Cell-Derived Factor-1, in the Development of Bone Marrow Metastases in Neuroblastoma. J Immunol, 2001; 167: 4747-4757
58. Muller A, Homy B, Soto H, Ge N, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001; 410: 50-56
59. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res, 2001; 61: 4961-4965
60. Scharder AJ, Lechner O, Templin M, et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer, 2002; 86: 1250-1256
61. Taichman RS, Cooper C, Keller ET, Pinta KJ, Taichman NS, Mccauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res, 2002; 62: 1832-1837
62. Burger M, Glodek A, Hartmann T, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation and adhesion to stromal cells. Oncogene, 2003; 22: 8093-8101
63. Hwang JH, Chung HK, Kim DW, et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab, 2003; 88: 408-416
64. Zeelenberg IS, Ruuls SL, Roos E. Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma.. J Clin Invest, 2001; 108: 269-277
65. Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res, 2002; 62: 2937-2941
66. Ding Shimada Y, Maeda M, et al. J Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res, 2003; 9: 3406-3412
67. Robledo MM, Bartolome RA, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem, 2001; 24: 24
68. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res, 2003; 9: 3625-3634
69. Kleihans M, Tun-Kyi A, Gilliet M, et al. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood. 2003; 101: 1487-1493
70. Jones D, Benjamin RJ, Shahsafi A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood. 2000; 95: 627-632
71. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002; 13: 143-154
72. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol, 2002; 72: 9-18
73. Zhang L, Conejo JR, Katsaos D. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med, 2003; 348: 203-213
74. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001; 357: 539-545
75. Nesbit M, Schader H, Miller TH, Herlyn M, Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol, 2001; 166: 6483-6490
76. Danel D, Meyer MN, Bergsland EK, Dehne K, Coussens LM, Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med, 2003; 197: 1017-1028
77. Skinnider BF, Elia AJ, Gascoyane RD, et al.. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99: 618-626
78. Negus RP, Stamp GW, Relef MG, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest. 1995; 95: 2391-2396
79. Milliken D, Scotton C, Rajij S, Balkwill F, Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res, 2002; 8: 1108-1114
80. Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res, 1999; 59: 4681-4687
81. Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res, 2002; 62: 1093-1102
82. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy.J Exp Med, 2001; 193: 727-740
83. Ohta M, Kitadi Y, Tanaka S, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer, 2002; 102: 220-224
84. Monti P, Leone BE, Marchesi, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res, 2003; 63: 7451-7461
85. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type Imembrane proteins. Science, 1993; 261: 600-603
86. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell, 2006; 124: 175-189
87. Katayama Y, Battista M, Kao WM, et al.. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell,2006; 124: 407-421
88. Petit I, Szyper-Kravitz M, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immuno, 2002; 3: 687-694
89. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Inves,t 2000; 106: 1331-1339
90. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature, 1998; 393: 595-599
91. Kryczek I, Grybos M, Dlubek D, Klimczak A, Rabczynski J, Lange A. Accumulation of CD45RO cells in peritoneal carcinomatous fluid favours survival of ovarian carcinoma patients. Cancer Immunol Immunother, 2002;. 51: 513-519
92. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 2001; 61: 4961-4965
93. Zou W, Machelon V, Coulomb, et al. Stromal derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Me, 2001;7: 1339-1346
94. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001; 410: 50-56
95. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002; 62: 1832-1837
96. Kang H, Watkins G, Parr C, et al. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res, 2005; 7: R402-R410
97. Rempel SA, Dudas S, Ge S, Gutierrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res2000; 6: 102-111
98. Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004; 64: 8420-8427
99. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003; 89: 462-473
100. Orimo, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348
101. Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell. 2005; 4: 291-298
102. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol2 003; 17: 792-803
103. Kryczek I, Lange A, Mottram P, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005; 65: 465-472
104. Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP. CXCR-4 ,a chemokine receptor, is overexpressed in and required for proliferation of lioblastoma tumor cells. J Surg Oncol, 1998; 69: 99-104
105. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res, 2001; 61: 6674-6678
106. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med, 2003; 167: 1676-1686
107. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930-5938
108. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol, 2003; 17: 792-803
109. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev, 1999; 20: 253-278
110. Lindgren P, Backstrom T, Mahlck CG, Ridderheim M, Cajander S. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int J Oncol, 2001; 19: 31-38
111. Wang CY, Mayo MW, Baldwin AS Jr. TNF and cancer therapyinduced apoptosis: potentiation by inhibition of NF-B. Science, 1996; 274: 784-787
112. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene, 2005; 24: 4462-4471
113. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med, 199; 5: 662-668
114. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via 1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene, 2000; 19: 4319-4327
115. Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res, 1999; 5: 1587-1594,
116. Muller A, Sonkoly E, Eulert C, et al. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer, 2006; 118: 2147-2157
117. Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA, 1999; 5: 9448-9453
118. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature, 1998; 393: 591-594
119. Molino M, Woolkalis MJ, Prevost N, et al. CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. Biochim Biophys Acta. 2000; 1500: 227-240
120. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1. Am J Pathol. 1999; 154: 1125-1135
121. Mirshahi F, Pourtau J, Li H, Muraine M, et al. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res. 2000; 99: 587-594
122. Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol Rev 2000; 177: 175-184
123. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res, 2004; 64: 5535-5538
124. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem. 1998; 273: 4282-4287
125. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1. Am J Pathol. 1999; 154: 1125-1135
126. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood. 2002; 99: 2703-2711
127. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10: 858-864
128. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003; 425: 307-311
129. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol. 2004; 14: 181-185
130. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2: 563-572
131. Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer, 2003; 97: 772-778
132. Hargreaves DC, Hyman PL, Lu TT, et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med. 2001; 194: 45-56
133. Cyster JG. Homing of antibody secreting cells. Immunol Rev. 2003; 194: 48-60
134. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol. 2003; 170: 1136-1140
135. Abroun S, Otsuyama KI, Shamsasenjan K, et al. Galectin-1 supports the survival of CD45RA(-) primary myeloma cells in vitro. Br.J Hematology. 2008 in press
136. Islam A, Otsuyama K, Abroun S, et al. SDF-1 Is Responsible for the Constitutively High NF-kB Activity in Human Myeloma Cells. Blood ASH Annual Meeting Abstracts 108, Issue 11
137. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999; 93: 1658-1667
138. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2: 161-174
139. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer. 2003; 89: 1817-1821,
140. -Yu X, Collin-Osdoby P, Osdoby P. SDF-1 increases recruitment of osteoclast precursors by upregulation of matrix metalloproteinase-9 activity. Connect Tissue Res. 2003; 44 Suppl 1: 79-84
141. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res, 2003; 63: 3833-3839
142. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol, 2001; 167: 4747-4757
143. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000; 6: 3530-3535
144. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov, 2003; 2: 581-587
145. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004; 37: 1253-1262
146. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34- cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol, 2004; 22: 1095-1102
147. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood, 2003; 102: 2728-2730
148. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005; 307: 58-62
149. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II ose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003; 30: 117-124
150. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan,fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
151. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol, 2003; 21: 60-65